NCT04980352

Brief Summary

This study aims to determine the clinical effectiveness of multi-dimensional signatures in predicting response and prognosis of lung cancer patients. The study is a multi-center perspective research of treatment planning for patients with lung cancer. To characterize clinical effectiveness, the progression-free survival (PFS) and overall survival (OS) impacts of multi-dimensional signatures will be estimated.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2021

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

July 11, 2021

Completed
17 days until next milestone

First Posted

Study publicly available on registry

July 28, 2021

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2024

Completed
Last Updated

July 28, 2021

Status Verified

July 1, 2021

Enrollment Period

3 years

First QC Date

July 11, 2021

Last Update Submit

July 26, 2021

Conditions

ResponsePrognosis

Keywords

Multi-dimensional SignaturesNGSLung Cancer

Outcome Measures

Primary Outcomes (1)

  • PFS

    Progression-free survival

    through study completion, an average of 6 months

Secondary Outcomes (1)

  • OS

    through study completion, an average of 1 year

Interventions

real world treatment by doctorsOTHER

real world treatment by doctors

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with locally-advanced or metastasis lung cancer

You may qualify if:

  • Patients with locally-advanced or metastasis lung cancer
  • Life expectancy \> 3 months

You may not qualify if:

  • Age at diagnosis \<18
  • refuse to enroll

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wuhan Union Hospital

Wuhan, Hubei, 430000, China

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Central Study Contacts

Yuan Li, Dr.

CONTACT

+862788041911liyuanpumc@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 11, 2021

First Posted

July 28, 2021

Study Start

January 1, 2021

Primary Completion

December 30, 2023

Study Completion

December 30, 2024

Last Updated

July 28, 2021

Record last verified: 2021-07

Locations

CN(1)